The PREP Repeal Act (H.R. 4388) repeals the statutory immunity provisions in sections 319F–3 and 319F–4 of the Public Health Service Act and rescinds unobligated balances in the Covered Countermeasure Process Fund. The bill also removes a cross-reference in the Federal Food, Drug, and Cosmetic Act and clarifies that people may pursue civil remedies under federal or state law for harm caused by drugs, devices, biologics, or covered countermeasures.
This is consequential: it would eliminate the primary federal shield that insulated manufacturers, distributors, and some providers from tort liability for countermeasures deployed during declared public health emergencies, and it would withdraw remaining administrative funds tied to the federal compensation process. That combination changes the incentives for private-sector partners and creates new litigation and budgetary questions for HHS and defendants alike.
At a Glance
What It Does
The bill repeals the PREP Act’s immunity provisions and the statutory funding mechanism for the federal countermeasure compensation process, rescinds unobligated balances in that fund, and deletes a statutory citation in the FD&C Act. It preserves citizens’ ability to sue under federal or state law and applies to both pending and new cases.
Who It Affects
Manufacturers, distributors, and administrators of vaccines, therapeutics, diagnostics, and other countermeasures; HHS programs that administered PREP-era compensation and grants; health-care providers that delivered countermeasures during emergencies; and plaintiffs (individuals and plaintiffs’ counsel) seeking compensation for injury.
Why It Matters
Removing statutory immunity shifts risk from a federal statutory regime back to ordinary tort law, likely increasing litigation and insurance exposure for private partners and providers. At the same time, rescinding unobligated funds may leave victims without the administrative compensation mechanism that accompanied the immunity framework, producing a new reliance and policy gap to resolve.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill dismantles the two PREP Act provisions that together created an immunity-and-compensation architecture for medical countermeasures used in public health emergencies. By repealing the immunity provision, the statute no longer provides a broad federal shield that protected manufacturers, distributors, and certain other actors from tort suits tied to covered countermeasures.
Simultaneously, repealing the companion provision that established the administrative fund removes the statutory vehicle Congress used to finance an administrative compensation process.
Beyond repeal, the bill instructs federal law to treat references to the repealed sections as though they remained as they were the day before enactment for interpretation purposes, and it makes a single-line amendment to the FD&C Act by removing a reference to the PREP immunity provision from the EUA-related statutory text. That amendment will change how liability-related cross-references operate for products authorized under emergency authority.The bill preserves a statement that individuals retain the right to bring civil claims under federal or state law for harm from drugs, devices, biologics, and covered countermeasures, and it expressly makes the repeal applicable to cases that are pending on enactment as well as cases filed afterward.
The combined effect is to reopen the courthouse doors to claims relating to past and future emergency countermeasures while also removing the nearby administrative fund that previously financed compensation options.Practically, the measure creates immediate legal and programmatic questions: defendants and insurers will reassess exposure for acts that occurred under prior immunity; HHS will need to reconcile contracts, outstanding obligations, and program administration with rescinded unobligated balances; and plaintiffs will decide whether to pursue administrative or judicial remedies. The bill includes a severability clause to prevent an invalidated provision from collapsing the rest of the Act.
The Five Things You Need to Know
The bill repeals 42 U.S.C. 247d–6d (the PREP Act immunity provision) and 42 U.S.C. 247d–6e (the statutory provision tied to the federal countermeasure compensation fund).
It rescinds unobligated balances in the Covered Countermeasure Process Fund that had been established under section 319F–4(a), removing statutory money set aside for compensation processes.
The bill amends 21 U.S.C. 360bbb–4(b)(1) (the FD&C Act EUA provision) by striking the statutory citation to the PREP Act immunity, altering the statutory cross-reference for emergency authorizations.
Section 4 preserves express statutory language that individuals may pursue civil remedies under federal or state law for injury from drugs, devices, biologics, or covered countermeasures (as previously defined).
Section 5 makes the repeal apply to both pending actions (including unexhausted appeals) and any actions commenced on or after the date of enactment, so liability exposure can be retroactive to ongoing cases.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short name, the 'PREP Repeal Act.' This is a conventional drafting device but anchors subsequent references and signage for the statute.
Congressional findings
Lists legislative findings criticizing liability shields under the PREP Act and asserting that immunity undermined trust and accountability. Findings carry no operative legal effect but can inform judicial interpretation and policy justification for the repeal; courts sometimes refer to findings when construing ambiguous provisions or assessing congressional intent.
Repeal of PREP immunity, repeal of fund provision, and technical amendments
Subsection (a) deletes the two statutory sections that together created the PREP immunity regime and the statutory apparatus for the federal countermeasure compensation fund. Subsection (b) rescinds unobligated balances in the Covered Countermeasure Process Fund, sending a message that money set aside under that statute is withdrawn. Subsection (c) directs that references to the repealed sections be read as they stood the day before enactment for interpretive consistency, and it amends the FD&C Act by striking '319F–3,' from a list of cross-references—altering how EUA-related authority links to PREP immunity in statute. Practically, this bundle both removes the statutory shield and strips legislative money that helped operationalize administrative compensation.
Preservation of private civil remedies
Affirms that the Act does not limit a person’s ability to pursue civil remedies under federal or state law for injury from drugs, devices, biologics, or covered countermeasures. This is an affirmative statement that plaintiffs retain traditional tort and statutory causes of action; it does not, however, create a federal compensation program—rather it restores access to courts and existing remedies that the repealed provisions had curtailed.
Application to pending and future actions
States that the Act applies to claims and proceedings that are pending on the date of enactment (including unexhausted appeals) and to any claims commenced after enactment. That language makes the repeal effectively retroactive for civil litigation still active at enactment and increases the number of potential cases against manufacturers and providers by removing thumbs-on-the-scale defenses that existed when the original conduct occurred.
Severability clause
Contains a standard severability provision to ensure that if a court invalidates one provision of the Act, the remainder remains in force. For stakeholders planning litigation or compliance steps, this limits the risk that a single judicial ruling could nullify the entire repeal package.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Injured individuals and their families — They regain or retain the ability to sue in state or federal court for harms tied to covered countermeasures, restoring access to traditional tort remedies that PREP immunity limited.
- Plaintiffs’ attorneys and consumers’ advocates — They gain clearer standing and potentially a larger docket of PREP-related claims to pursue, including cases that were previously barred by the immunity framework.
- State attorneys general and state courts — States regain broader enforcement and adjudicative authority over claims involving countermeasures, increasing avenues for state-level consumer protection and remedies.
- Public accountability organizations — Groups seeking transparency and corporate accountability will find statutory backing for litigation and information access that immunity had impeded.
Who Bears the Cost
- Pharmaceutical and medical device manufacturers — They face increased tort exposure, potential class actions, higher defense costs, and upward pressure on product liability insurance premiums for countermeasures used in emergencies.
- Health-care providers and administrators — Hospitals, clinics, and clinicians who administered countermeasures may face more lawsuits or subpoenas and will need to reassess indemnity arrangements and malpractice exposure during emergencies.
- HHS and federal programs — Rescinding unobligated fund balances removes a statutory funding source for administrative compensation and forces programmatic and budgetary reevaluation; HHS may confront contractual and operational gaps.
- Insurers and underwriters — Private insurers who cover manufacturers, providers, or distributors may see increased claims and may revise terms, limits, or exclusions for pandemic-related exposures, affecting coverage availability and cost.
Key Issues
The Core Tension
The central tension is accountability versus operational incentives: the bill restores individuals’ access to courts and corporate accountability for harms but does so by eliminating the liability protections that incentivized rapid private-sector involvement in emergency countermeasure development and deployment—creating a trade-off between legal redress for victims and the practical capacity to mount fast, large-scale public health responses.
The bill resolves one problem—statutory immunity—while opening multiple difficult implementation questions. Removing immunity without replacing the administrative compensation mechanism creates a gap: victims who might previously have received streamlined, capped administrative relief now must pursue ordinary litigation, which is slower, more expensive, and uncertain.
At the same time, rescinding unobligated fund balances could impede any remaining administrative process and leave HHS without the statutory cash to settle or process claims it previously intended to fund.
Retroactive application to pending cases produces reliance and fairness issues. Defendants that acted in good faith under a statutory immunity regime may raise equitable defenses, estoppel, or constitutional challenges based on reliance or separation-of-powers doctrines; courts will be asked to reconcile those defenses with the Act’s explicit retroactivity language.
The FD&C Act citation change also creates statutory uncertainty for products authorized under emergency authorities—litigants and agencies will litigate whether ERA-linked protections survive or are extinguished by the repeal. Lastly, the measure balances accountability with the risk of chilling private participation: removing legal shields may increase transaction costs and deter companies from investing in countermeasure development or entering public-private emergency contracts without additional indemnities or federal guarantees.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.